Cannabis Science, Inc. (CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis-based products, is pleased to provide an update on its recent acquisition of the "Trimcare Brand". Cannabis previously announced the acquisition on June 11, 2012.
Since that time, while further reviewing the agreements, both parties realized that due to some legal issues regarding licensing and ownership of certain assets the agreements need to be re-drafted.
The parties are currently working with the attorney's on revising the finalized documents and once the documents are finalized, Cannabis will make its filings with the S.E.C. disclosing the acquisition.
Dr. Ivan Goldsmith has provided 20 years of professional service within the Las Vegas community. Trimcare has 5,000 active patients consisting of in and out of state patients, who are being treated by internal medicine, bariatrics, and anti-aging methods. Trimcare is a premier integrated weight loss and anti-aging clinic in Las Vegas. Also providing a number of additional services such as a "Physician Dispensing Pharmacy". Cannabis Science comes together with Goldsmith Heath Care, in plans to expand the Trimcare line across the US in every major metropolis. These plans consist of opening up a second, third and fourth location in Las Vegas. Cannabis Science is currently in negotiations to open up the second clinic, in Henderson, Las Vegas. The first clinic already resides at 4240 West Flamingo Rd in Las Vegas and is 5,000 square feet.
Dr. Ivan Goldsmith and his staff will continue to work with Cannabis Science immensely. In addition to expanding operations, the Companies will combine their formulations along with medical cannabis to bring together a new line of products, ranging from all areas of medical and cosmetic needs. Trimcare is active in alternative delivery methods such as creams, pellets, patches, and transdermal skin delivery systems. Trimcare currently has 30 over-the-counter products on the market. Making up these product lines are supplements, skin care products, food, and hormone products. From inception, manufacturing, commercialization, relationships and products, Dr. Goldsmith has brought these 30 products to the market himself, and Cannabis Science plans to use his expertise and integrate them into its future line of products as well.
Cannabis Science will add many new additions to its team within its Executive Management, Scientific Advisory Board and Policy Advisory Board, including Trimcare employees, will have almost 30 staff members ranging from a wide variety of expertise.
For further information about Trimcare and Dr. Ivan Goldsmith, you can go to the Trimcare website, www.trimcare.com or read the previous news release on the Cannabis Science website www.cannabisscience.com, dated May 3, 2012 or click this link, http://www.cannabisscience.com/news-a-media/press-releases/292-cannabis-science-teams-with-dr-ivan-goldsmith-of-trimcare-in-las-vegas-for-innovative-weight-loss-programs-based-on-research-of-the-endocannabinoid-system.html.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
Robert Kane, 1-561-234-6929
VP Investor Relations